Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Other Working Capital Changes (2018 - 2025)

Historic Other Working Capital Changes for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to -$84.0.

  • BioNexus Gene Lab's Other Working Capital Changes rose 9595.38% to -$84.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $35606.0, marking a year-over-year increase of 21984.11%. This contributed to the annual value of $95879.0 for FY2024, which is 2513.57% up from last year.
  • Latest data reveals that BioNexus Gene Lab reported Other Working Capital Changes of -$84.0 as of Q3 2025, which was up 9595.38% from -$10616.0 recorded in Q2 2025.
  • In the past 5 years, BioNexus Gene Lab's Other Working Capital Changes registered a high of $120221.0 during Q4 2024, and its lowest value of -$77276.0 during Q1 2022.
  • In the last 5 years, BioNexus Gene Lab's Other Working Capital Changes had a median value of -$6375.0 in 2021 and averaged $2263.2.
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first plummeted by 111217.25% in 2022, then surged by 233916.93% in 2024.
  • Quarter analysis of 5 years shows BioNexus Gene Lab's Other Working Capital Changes stood at $93112.0 in 2021, then tumbled by 153.07% to -$49410.0 in 2022, then surged by 89.13% to -$5369.0 in 2023, then soared by 2339.17% to $120221.0 in 2024, then tumbled by 100.07% to -$84.0 in 2025.
  • Its Other Working Capital Changes stands at -$84.0 for Q3 2025, versus -$10616.0 for Q2 2025 and -$73915.0 for Q1 2025.